SEP 20, 2019 6:43 PM PDT

Leukemia Drug Effective for Treating Childhood Brain Cancer

WRITTEN BY: Nouran Amin

Scientists at the University of California-San Diego have found that a chronic myeloid leukemia drug was found to treat medulloblastoma in mouse models more effectively than existing therapeutics. Findings of the study were published in PLOS One and demonstrates how the use of the single FDA-approved drug ‘nilotinib’ targets cancer cells that have been abnormally activated through a specific cell communication system known as the Hedgehog pathway.

Learn more about the Hedgehog Pathway:

"We discovered a previously unknown activity of nilotinib that may be leveraged to treat a large fraction of cases of medulloblastoma, a type of childhood brain cancer," said senior author Ruben Abagyan, PhD, professor in the Skaggs School of Pharmacy. "While more research is needed, this pharmaceutical could potentially be used for several cancer types with an overactive cell-signaling pathway."

Many types of cancer have an impaired hedgehog pathway such as basal cell carcinoma, myeloid leukemia, rhabdomyosarcoma, pancreatic adenocarcinoma, glioblastoma and one third of medulloblastoma cases. The Hedgehog pathway is a critical cellular system that regulates embryonic development and adult tissue regeneration. When impaired, the pathway allows the cancer cells to overproduce a cell-surface receptor known as smoothened—this results in plenty of malignant cancers.

In the study, Nilotinib was found to inhibit the activity of smoothened and several other protein kinases implicated in tumor growth. This was demonstrated in mice bearing human medulloblastoma tumors which after the Nilotinib-treatment tumor growth was decreased with no apparent drug resistance.

"Only a fraction of patients with this subtype of medulloblastoma respond well to current therapies that only target Smoothened," said Abagyan. "Knowing that dysregulation of the Hedgehog pathway is important to the maintenance of cancer stem cells, and that it plays a critical role in several cancers, we wanted to find a single drug that inhibits this pathway in addition to several other essential anti-cancer activities."

Source: Science Daily

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
APR 27, 2021
Cannabis Sciences
CBD Doesn't Reduce Pain, but Makes it Less Unpleasant
APR 27, 2021
CBD Doesn't Reduce Pain, but Makes it Less Unpleasant
While anecdotal reports tout cannabidiol’s (CBD) utility for pain relief, up until now, there’s been limited ...
MAY 04, 2021
Immunology
One Vaccine to Rule Them All
MAY 04, 2021
One Vaccine to Rule Them All
There are currently five variants of concern in the U.S., genetically distinct forms of the COVID-causing coronavirus th ...
MAY 04, 2021
Cell & Molecular Biology
A Potential Weakness in SARS-CoV-2 is Caught on Video
MAY 04, 2021
A Potential Weakness in SARS-CoV-2 is Caught on Video
You can see the spike protein of the virus in action in this video.
MAY 18, 2021
Immunology
A Silver Bullet Against COVID Variants?
MAY 18, 2021
A Silver Bullet Against COVID Variants?
Canadian researchers have discovered an antiviral drug that blocks the SARS-CoV-2 virus from infecting lung cells. Promi ...
JUN 24, 2021
Immunology
Should We Rethink COVID Vaccine Recipes?
JUN 24, 2021
Should We Rethink COVID Vaccine Recipes?
In a study reported in the journal Cell, immunologists provide evidence for an Achilles’ heel in current COVI ...
JUL 15, 2021
Drug Discovery & Development
The genomics of high blood pressure - a road to the future of treatment
JUL 15, 2021
The genomics of high blood pressure - a road to the future of treatment
The human heart begins to beat in utero in the early weeks of development and continues throughout life. In an average l ...
Loading Comments...